ID   TOV-3133D
AC   CVCL_9T19
SY   TOV3133D
DR   cancercelllines; CVCL_9T19
DR   CancerTools; 161899
DR   Wikidata; Q54972814
RX   PubMed=22931248;
CC   Doubling time: 2.63 +- 0.11 days (PubMed=22931248).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Unspecified (PubMed=22931248).
CC   Miscellaneous: STR profile from personal communication of Mes-Masson, Anne-Marie.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 13
ST   D16S539: 13
ST   D21S11: 30,32.2
ST   D5S818: 12
ST   D7S820: 8,12
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9T15 ! OV-3133(R)
OI   CVCL_9T16 ! OV-3133(R2)
OI   CVCL_4064 ! TOV-3133G
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 10-04-25; Version: 13
//
RX   PubMed=22931248; DOI=10.1186/1471-2407-12-379; PMCID=PMC3532154;
RA   Letourneau I.J., Quinn M.C.J., Wang L.-L., Portelance L., Caceres K.Y.,
RA   Cyr L., Delvoye N., Meunier L., de Ladurantaye M., Shen Z.,
RA   Arcand S.L., Tonin P.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Derivation and characterization of matched cell lines from primary
RT   and recurrent serous ovarian cancer.";
RL   BMC Cancer 12:379.1-379.16(2012).
//